Form 4: Cardio Diagnostics Director Acquires Stock Options

Cardio Diagnostics Holdings, Inc. Director Wendy J Betts acquired 1,736 stock options with an exercise price of $3.60, effective June 30, 2025.

Summary

• Wendy J Betts, a Director of Cardio Diagnostics Holdings, Inc. (CDIO), acquired 1,736 stock options.
• The acquired stock options have an exercise price of $3.60 per share.
• The transaction date for the acquisition of these options is June 30, 2025.
• Each stock option represents the right to buy one share of Cardio Diagnostics Holdings, Inc. Common Stock.
• Following this reported transaction, Wendy J Betts beneficially owns a total of 2,443 derivative securities.
• The acquired options become exercisable on June 30, 2025, and are set to expire on June 30, 2035.

Sentiment

Score: 6

Explanation: The acquisition of stock options by a director is generally a positive signal, indicating confidence in the company's future. However, it's a routine compensation event and not a major strategic announcement, hence a moderate positive score.

Positives

• A director acquiring stock options can signal confidence in the company's future performance and growth prospects.
• The acquisition of options aligns the director's financial interests directly with those of the company's shareholders, incentivizing long-term value creation.

Risks

• The value of the acquired stock options is contingent upon the future market price of Cardio Diagnostics Holdings, Inc. common stock exceeding the exercise price of $3.60.
• If the company's stock price does not rise above the exercise price by the expiration date, the options may expire worthless, resulting in no financial gain for the holder.

Future Outlook

The acquisition of stock options by a director suggests an expectation of future stock price appreciation, as the options only hold intrinsic value if the stock price rises above the exercise price of $3.60.

Industry Context

This transaction is a routine insider filing, common across all industries, reflecting equity compensation or personal investment by a director. It does not provide specific insights into broader industry trends for the healthcare or diagnostics sector, but rather reflects internal corporate governance and compensation practices.

Comparison to Industry Standards

• The granting of stock options as part of director compensation is a standard practice across publicly traded companies, including those in the healthcare and diagnostics industry.
• This practice aligns director incentives with shareholder value creation, a common corporate governance principle.
• The specific exercise price of $3.60 for these options is unique to Cardio Diagnostics Holdings, Inc. and cannot be directly compared to industry-wide benchmarks without knowing the company's current stock price and historical volatility relative to its peers.

Stakeholder Impact

• Shareholders: The acquisition of options by a director aligns their interests with shareholders, potentially signaling confidence in future stock performance and long-term value creation.

Key Dates

Keywords

Cardio Diagnostics Holdings Inc., CDIO, SEC Form 4, Insider Transaction, Stock Options, Director Compensation, Equity Compensation, Beneficial Ownership